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Manipulation of T-cell co-inhibitory molecules, such as
CTLA-4, PD-1, and BTLA has recently moved to the
forefront of cancer immunotherapy. Although these
molecules serve as inhibitors of T-cell activation, they
are also biomarkers for activated T cells and may in fact
have positive immune regulatory functions under certain
circumstances. Recently, we demonstrated an unexpected
positive association of CD8+ T cells expressing BTLA (B-
and T- lymphocyte attentuator) with clinical response to
adoptive T cell therapy in late-stage melanoma patients.
We hypothesized that TIL may utilize the BTLA check-
point differently and that key phenotypic and functional
differences may exist between CD8+BTLA+ and CD8+
BTLA- TIL subsets. In this study, we isolated and charac-
terized BTLA+ and BTLA- CD8+ TIL from melanoma
patients accrued in a Phase II clinical trial. We found that
CD8+BTLA+ TIL had a superior proliferative response to
IL-2 and a younger, more central memory T-cell behavior,
such as secreting their own IL-2 after TCR stimulation.
This younger and more robust memory phenotype was
also associated with a longer persistence of T-cell clones
in vivo in patients from the infused CD8+BTLA+ TIL
subset. In contrast, CD8+BTLA- TIL were poorly prolif-
erative, expressed killer-cell immunoglobulin-like recep-
tors, and exhibited a gene expression signature of T cell
deletion. As previously demonstrated, BTLA ligation with
its cognate ligand herpes virus entry mediator (HVEM)
resulted in decreased proliferation and inflammatory cyto-
kine secretion. However, in a model of TIL activation
induced cell death, we observed an enhanced survival of
TIL co-cultured with HVEM+ target cells suggesting that
BTLA ligation may also promote T-cell survival. Using a
recombinant HVEM-Fc protein, we found that HVEM
ligation of BTLA on CD8+ TIL activated the PI3K-Akt
pathway resulting in the phosphorylation of Akt; this
response was blocked using an anti-BTLA antibody. PI3K-
Akt activation is most likely mediated by a unique GRB2-
binding domain that exists in BTLA that can recruit PI3K
via GRB2. As HVEM is expressed by many melanoma
tumors and antigen-presenting cells these results suggest
that HVEM ligation of BTLA on CD8+BTLA+ effector
T-cells in the tumor microenvironment may play a dual
role by reducing over-stimulation through the TCR and
driving a PI3K-Akt-induced cell survival pathway. This
survival signaling pathway may facilitate the longer persis-
tence of the CD8+BTLA+ TIL subset in vivo in our
patients. Our study has uncovered a novel role for BTLA
both as a biomarker in TIL therapy and as a rheostat in
perhaps fine tuning CD8+ T-cell responses rather than
simply as a negative signaling pathway.
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